No Data
Chiome Bioscience and OmniAb Collaborate on Antibody Research
Sony Group Corp has revised its forecast upwards for March 25, with operating profit of 1 trillion 335 billion yen, up from 1 trillion 310 billion yen.
Sony Group Corp (6758) announced a revision of its Financial Estimates for the fiscal year ending March 2025. Revenue has been revised upwards from 12 trillion 710 billion yen to 13 trillion 200 billion yen, and operating profit from 1 trillion 310 billion yen to 1 trillion 335 billion yen. Entertainment-related segments such as Gaming and music are performing steadily. Additionally, it was announced that a share buyback program with a cap of 50 billion yen has been established, allowing the purchase of up to 30 million shares (0.5% of the total issued shares excluding treasury shares) in the market. 【Positive evaluation】<675
Chiome Bioscience Reports Modest Sales Growth Amid Continued Financial Challenges
Chiome Bioscience: Financial results supplementary materials for the fiscal year ending 2024/12
Chiome Bioscience: Summary of financial results for the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Chiome Bioscience FY Parent Loss Y1.02B Vs Loss Y1.22B